Advertisement

Bio Business

» tuberculosis, biotech, FDA and cancer

Most Recent

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

1 Comment

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: That Loving Feeling

That Loving Feeling

By | July 1, 2014

There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.

1 Comment

image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

1 Comment

image: Outwitting the Perfect Pathogen

Outwitting the Perfect Pathogen

By | January 1, 2014

Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.

0 Comments

image: Penetrating the Brain

Penetrating the Brain

By | November 1, 2013

Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.

2 Comments

image: Remaking a Classic

Remaking a Classic

By | September 1, 2013

Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.

0 Comments

image: How Safe Is Your Medicine Cabinet?

How Safe Is Your Medicine Cabinet?

By | May 1, 2013

After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.

1 Comment

image: The Little Cell That Could

The Little Cell That Could

By | July 1, 2012

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

1 Comment

image: Braving the IPO Drought

Braving the IPO Drought

By | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

0 Comments

Popular Now

  1. Staying Active in the Lab
    Careers Staying Active in the Lab

    Retiring as a professor, and even shutting down your own lab, doesn’t necessarily mean quitting research.

  2. When Does a Smart Mouse Become Human?
  3. The Lies That Scars Tell
    Notebook The Lies That Scars Tell

    Macaque trainers in Bangladesh are often bitten by their monkeys, but rarely infected by a particular simian retrovirus.

  4. Antibiotic Resistance Can Boost Bacterial Fitness
Advertisement
Advertisement
The Scientist